Targeted drug takes aim at Hard-to-Treat lung cancer

NCT ID NCT06933329

Ongoing Disease control Sponsor: BicycleTx Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests an experimental drug called zelenectide pevedotin in 73 people with advanced or metastatic non-small cell lung cancer that has a specific genetic change (NECTIN4 amplification) and has already been treated with at least one prior therapy. The drug is given intravenously on days 1 and 8 of each 21-day cycle. The main goal is to see how many patients' tumors shrink or disappear, while also monitoring side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zelenectide pevedotin (BT8009)
What this could lead to: If successful, this could point toward a new treatment option for people with a specific genetic subtype of advanced lung cancer that has stopped responding to standard therapies.
What could go wrong: This is a mid-stage trial with only 73 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors in enough patients to move forward.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Complejo Hospitalario Universitario A Coruña

A Coruña, 15006, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Institut Curie

Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.